Health Professionals

Clinical Updates

17 May 2013

Quadrivalent meningococcal vaccine (ACW135Y) for travel  

Quadrivalent meningococcal meningitis vaccine is recommended for some individuals who are travelling or going to reside in areas where there is a risk of acquiring meningococcal infection. Risk areas and recommendations for vaccination can be found on the NaTHNaC Country Information Pages.

Two conjugated quadrivalent (groups A, C, W135 and Y) meningococcal meningitis vaccines have a marketing authority for use in the UK:

Menveo®: manufactured and distributed by Novartis UK and

Nimenrix®: manufactured and distributed by GlaxoSmithKline

Conjugated meningococcal vaccines (Conjugate MenACWY) are more immunogenic in young children and are considered to give a longer duration of protection in all age groups compared with polysaccharide MenACWY vaccine (ACWYVax). For this reason, Conjugate MenACWY vaccine is the preferred option for all travellers at risk of meningococcal disease [1].

As of 7 May, 2013 guidance on the use of these vaccines for travellers has been updated. 

Recommendations for the preferred vaccine to use in different traveller age groups are: [1]:

Age (years)

Vaccine

Infants under one year**

Menveo®

  • First dose of 0.5 ml

  • Second dose of 0.5ml one month after the first dose

1 - 4

Menveo® or Nimenrix®

  • Single dose of 0.5ml

5 – 10

Either Menveo® or Nimenrix® (preferred to polysaccharide vaccine)

  • Single dose of 0.5ml

 

OR ACWYVax

  • Single dose of 0.5ml

 

≥11

Either Menveo® or Nimenrix®

(preferred to polysaccharide vaccine)

  • Single dose of 0.5ml

 

OR ACWYVax

  • Single dose of 0.5ml

 

** for advice on infants who require Conjugate MenACWY at the same time as routine Conjugate MenC vaccine please refer to Green Book.

 

The need for and timing of re-enforcing (booster) dose of Conjugate MenACWY has not been established [1].  Health professionals are advised to consult SPC for information about individual products [2, 3].

Health professionals should note that guidance in the Green Book may differ from that provided by the manufacturer in the Summary of Product Characteristics. However, the GB guidance, which is based on expert advice from the Joint Committee of Vaccination and Immunisation, should be followed.

References

1. Meningococcal. Ch 22. In: Salisbury D, Ramsay M, Noakes K (eds). Immunisation against infectious disease 2006. The Stationary Office, London. Available at: https://www.gov.uk/government/uploads/system/uploads/

attachment_data/file/195250/Green_Book_Chapter_

22_v2_2A.PDF

2. Novartis Vaccines. Summary of Product Characteristics: Menveo Group A, C. W135, Y conjugate vaccine. [Accessed 17 May, 2013]. Available at: http://www.medicines.org.uk/emc/medicine/22866/SPC/

Menveo+Group+A%2c+C%2c+W135+and+Y+

conjugate+vaccine/

3. GlaxoSmithKline UK. Summary of Product Characteristics: Nimenrix. [Accessed 17 May, 2013]. Available at: http://www.medicines.org.uk/emc/medicine/26514/SPC/

Nimenrix/

 

Links

GlaxoSmithKline UK. ACWY VAX. Summary of Product Characteristics

GlaxoSmithKline UK. Nimenrix. Summary of Product Characteristics

Joint Committee on Vaccination and Immunisation

Novartis Vaccines. Menveo. Summary of Product Characteristics

NaTHNaC Health Information Sheet: Meningococcal meningitis

Health Protection Agency: Meningococcal fact sheet